COVID-19 Update

Non-Clinicians / Medical Office Support Staff / Industry Participants

Due to the global COVID-19 pandemic and rapidly evolving public health organization guidance pertaining to its response, PAINWeek has made the decision to postpone the St. Louis PAINWeekEnd scheduled for April 18.

As you are undoubtedly aware, the Centers for Disease Control and Prevention (CDC) has recommended that in-person events comprising 50 or more attendees not be held for the next 8 weeks. Concurrently, various state and local authorities have begun directing the closure of bar, restaurant, and public service establishments in their jurisdictions. In view of the critical importance of these and other social distancing measures to attenuate the spread of infection and its impact on the healthcare system, we believe this postponement of our upcoming conferences is unavoidably necessary. A revised schedule for this conference will be developed and provided as soon as possible. Your registration will automatically transfer to the new date; however, you may request an immediate refund of your registration fee if you prefer.

If you made airline reservations, we recommend that you contact the airline to cancel. Most major carriers have added flexible change and cancellation policies. If you had plans to stay overnight, please contact the hotel directly to cancel your reservation.

We greatly regret the impact of this postponement on our attendees’ professional schedules and their interest in pain management education. As primary care practitioners, many of you are truly on the front lines of patient care in your communities, now more than ever in this uncertain time.

We are looking into adding more virtual and distance learning options. In the meantime, if you haven’t already done so, we recommend visiting the online education section of our website that includes articles, videos, interviews with thoughts leaders, and our PAINWeek Journal. We have also recently posted a webcourse entitled "Understanding and Addressing the Global Spread of the COVID-19 Infection: A Clinician's Guide" that is certified for 1-hour of CME/CE credit.

Please contact us with any questions or issues pertaining to your registration. Please accept our thanks for your understanding and support.

Saturday, May 16, 2020


    Coffee will be served.

  • Pain Management at Ground Zero

    West Virginia continues to lead the nation, and world, in drug overdoses, which makes one ponder what is being done at the “ground zero” of the opioid epidemic to save and improve lives. Where better than where it’s worst should some of the possible solutions come from? In 2016, an interprofessional panel of experts in pain management—ranging from medicine, osteopathy, nursing, pharmacy, dentistry; public health; the state PDMP; and representatives from insurance providers—was put together with aims of finding possible solutions. The West Virginia Safe & Effective Management of Pain (SEMP) Guidelines ( were developed to facilitate the shift of the best practices in pain management becoming the new standard of care. The SEMP Guidelines include 2 main components including the risk reduction strategy and the clinical treatment algorithms. Pain management algorithms are not available anywhere else in the entire world! So we would like to welcome you to “the West Virginia Way” and see just how the “wild and wonderful” state of West Virginia is approaching the opioid epidemic from a true ground zero. After all, if it works where it’s worst, how could it not help your state or your practice?

    • UAN: 0530-0000-20-043-L04-
    • AANP Rx Hours: 0.00

    Breakfast will be served.

    *This session is not certified for credit.


  • Opioid Moderatism: Seeking Middle Ground

    Few would question the severity of the prescription opioid crisis of the early years of this millennium, the causes of which were myriad. Undoubtedly, society needed to address the crisis in an aggressive manner. Unfortunately, the manner in which the problem was addressed has been a classic example of “overkill,” resulting in a war on opioid analgesia, the patients who require opioid treatment, and the providers who have continued to prescribe. Although many have cast blame on the 2016 CDC Opioid Prescribing Guideline, it was not necessarily the Guideline itself that caused so much suffering, but rather its weaponization. Irrespective, patients have been the “collateral damage” in this war on opioids. This presentation will address the imperative of physicians exercising more thorough and consistent opioid risk mitigation in order to avoid opioid analgesia from becoming further “legislated away,” as well as the imperative of those who are “pro-opioid” and “anti-opioid” to agree on a rational middle ground that is more “pro-patient.”

    • UAN: 0530-0000-20-047-L04-
    • AANP Rx Hours: 0.00
  • Drugs, Documentation, and DEA: Improving Your Charting of Prescribing Rationale in 2020 and Beyond

    Overlooking the importance of carefully documenting the rationale for the use of a controlled medication can land a prescriber in hot water with their licensing board or the DEA. This course will focus on what it takes to move beyond the problems associated with both EMR and handwritten medical charts, and into the documentation of cogent notes signaling proper patient evaluation, including risk evaluation, rationale for the use of controlled medication, and ongoing encounters with the patient.

    • UAN: 0530-0000-20-027-L03-P
    • AANP Rx Hours: 0.00



    Lunch will be served.

    Sponsored by AstraZeneca-Daiichi Sankyo, Inc.

    *This session is not certified for credit.

  • Mirror Mirror on the Wall: Who's the FDA's Fairest ADF of All?

    Challenge accepted. Our country has made numerous strides in advancing patient care, and more particularly conducting efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse deterrent formulation (ADF) opioid medications, with the aim of preventing the transition from the misuse and/or abuse of prescription opioid medications to illicit (and possibly laced) diacetylmorphine (aka heroin). How do these formulations work, one might ask? Which ADF opioid medications are not only available on the us market, but also specifically approved as an ADF opioid medication? Are these ADFs really foolproof? Well, the street chemists of our country have already accepted the challenge to be knowledgeable on all of the above. Now it’s our turn as healthcare professionals to get up to speed on these risk reduction entities.

    • UAN: 0530-0000-20-042-L04-P
    • AANP Rx Hours: 0.80


    Refreshments will be served.

    *This session is not certified for credit.

  • Reefer Madness Revisited: Taking the Insanity Out of Medical Cannabinoids

    Medical, and recreational, marijuana serve as sources of great confusion to patients and clinicians alike. A culture of “neuromysticism” around medical marijuana has arisen, leaving patients and clinicians alike confused regarding what constitutes “medical” marijuana. A part of this confusion is related to the poor quality of the available research on safety and efficacy, which are due, in part, to the restrictive scheduling of the drug. This lecture will focus on what we know, and what we don’t know, about the efficacy and safety of medical cannabinoids. Specific recommendations regarding the safest and most effective use of medical marijuana as part of a pain management armamentarium will be provided.

    • UAN: 0530-0000-20-049-L04-
    • AANP Rx Hours: 0.00
  • Through the Eyes of an Expert Witness: The Importance of Chart Documentation in the Chronic Pain Patient

    Those who have been on either side of a courtroom battle on chronic opioid therapy have seen experts and lawyers spend a great deal of time arguing about the extent and nature of risk mitigation and patient education necessary to demonstrate that the prescriber issued a valid controlled substance prescription. The focus of expert testimony is on whether the prescriber engaged in meaningful risk evaluation and monitoring practices, and whether the prescriber individualized medical care for the patient, based on specific history and behaviors as treatment went on. This course will use published medical expert testimony and common expert reports of illegal and insufficient risk mitigation and patient education. The main goal is to facilitate a prescriber's self-audit of risk mitigation practices and to help attendees improve documentation of risk mitigation protocols and patient education efforts. A proactive approach to meaningful risk mitigation is necessary for protecting patient access to quality pain care and creating a framework within which other practitioners may confidently assume care for patients when necessary, and demonstrating appropriate prescribing of chronic opioid therapy.

    • UAN: 0530-0000-20-035-L01-P
    • AANP Rx Hours: 0.00